Can response to interferon treatment in chronic hepatitis C be influenced?;PEUT-ON AGIR SUR LES FACTEURS DE RESISTANCE AU TRAITEMENT PAR INTERFERON DE L'HEPATITE CHRONIQUE C?

Hepato-Gastro

Volumn 5, Issue 1, 1998, Pages 35-44

  Eugène, Claude ^a  

^a CENTRE HOSPITALIER INTERCOMMUNAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ALCOHOL; INTERFERON; URSODEOXYCHOLIC ACID;

ALCOHOL LIVER DISEASE; ALCOHOLISM; CHRONIC HEPATITIS; DRUG EFFICACY; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; META ANALYSIS; OBESITY; PATIENT; REVIEW;

EID: 0031934385     PISSN: 12537020     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (71)

1. Tine F, Magrin S, Craxi A, Pagliaro L. Interferon for non-A, non-B hepatitis A meta-analysis of randomised clinical trials. J Hepatol 1991 , 13 : 192-9.
2. Serfaty L, Giral P, Loria A, Andréani T, Legendre C, Poupon R. Factors predictive of the response to interferon in patients with chronic hepatitis C J Hepatol 1994 ; 21 : 12-7.
3. Marcellin P, Pouteau M, Martinot M, Boyer N, Castelnau C, Benhamou JP, et al. Facteurs de réponse au traitement par l'interféron alpha chez les malades atteints d'hépatite chronique C. Gastroenterol Clin Biol 1995 ; 19 . 991-1000
4. Bonkovsky HL, Banner BF, Rothman AL. Iron and chronic viral hepatitis. Hepatology 1997 ; 25 : 759-68.
5. Bayraktar Y, Koseoglu T, Sommer C, Kayhan B, Temizer A, Uzunalimoglu B, et al The use of deferoxamine infusions to enhance the response rate to interferon-α treatment of chronic viral hepatitis B. J Viral Hep 1996 ; 3 : 129-35.
6. Bacon BR, Farahvash MJ, Janney CG, Neuschwander-Tetri BA Nonalcoholic steatohepatitis : an expanded clinical entity Gastroenterology 1994 , 107 1103-9
7. Di Bisceglie AM, Axiotis CA, Hoofnagle JH, Bacon BR. Measurements of iron status in patients with chronic hepatitis. Gastroenterology 1992 ; 102 : 2108-13.
8. Farinati F, Cardin R, De Maria N, Libera GD, Marafin C, Lecis E et al. Iron, storage, lipid peroxidation and glutathione turnover in chronic anti-HCV positive hepatitis. J Hepatol 1995 ; 22 . 449-56
9. Arber N, Konikoff FM, Moshkowitz M, Baratz M, Hallak A, Santo M, et al. Increased serum iron and iron saturation without liver iron accumulation distinguish chronic hepatitis C from other chronic liver diseases. Dig Dis Sci 1994 ; 39 2656-9.
10. Ikura Y, Morimoto H, Johmura H, Fukui M, Sakurai M. Relationship between hepatic iron deposits and response to interferon in chronic hepatitis C. Am J Gastroenterol 1996 , 91 : 1367-73
11. Izumi N, Enomoto N, Uchichara M, Murakami T, Onon K, Noguchi O, et al. Hepatic iron content and response to interferon-α in patients with chronic hepatitis C. Relationship to genotypes of hepatitis C virus Dig Dis Dig 1996 , 41 . 989-94.
12. Van Thiel DH, Fiedlander L, Fagiuoli S, Weight HI, Irish W, Gavaler J. Response to interferon α therapy is influenced by the iron content of the liver. J Hepatol 1994 ; 20 410-5.
13. Caraceni P, Fagiuoli S, Van Thiel DH. Iron reduction therapy : simply camouflage or a real weapon ? Am J Gastroenterol 1994 ; 89 : 970-2.
14. Piperno A, et al. Can iron depletion therapy ameliorate hepatocellular injury in anti-HCV positive chronic hepatitis ? Gastroenterology 1992 ; 102 : A868.
15. Hayashi H, Talikawa T, Nishimura N, Yano M, Isomura T, Skamoto N Improvement of serum aminotransferase levels after phlebotomy in patients with chronic hepatitis C and excess hepatic iron Am J Gastroenterol 1994 ; 89 : 986-8
16. Hayashi H, Talikawa T, Nishimura N, Yano M Serum aminotransferase levels as an indicator of the effectiveness of venesection for chronic hepatitis C. J Hepatol 1995 ; 22 : 268-71.
17. Deugnier YM, Turlin B, Powell LW, et al Differentiation between heterozygotes and homozygotes in genetic hemochromatosis by means of a histological hepatic iron index : a study of 192 cases. Hepatology 1993 , 17 : 30-4.
18. Piperno A, Sampierro M, D'Alba R, Roffi L, Fargion S, Parma S, et al. Iron stores, response to α-interferon therapy, and effects of iron depletion in chronic hepatitis C. Liver 1996 , 16 . 248-54
19. Pouteau M, Courtois F, Martinot M, Atassi-Dumont M, Erlinger S, Marcellin P Effects of phlebotomy in patients with chronic hepatitis C non responders to interferon therapy. Hepatology 1996 , 24 : 404A.
20. Olynyk JK, Reddy KR, Di Bisceglie AM, Jeffers LJ, Parker TI, Radick JL et al Hepatic iron concentration as a predictor of response to interferon alfa therapy in chronic heoatitis C Gastroenterology 1995 , 108 1104-9
21. Barton AL, Banner BF, Cable EE, Bonkovsky HL Distribution of iron in the liver predicts response of chronic hepatitis C infection to interferon therapy. Am J Clin Pathol 1995 ; 103 : 419-21.
22. Banner BF, Barton AL, Cable EE, Smith L, Bonkovsky HL. A detailed analysis of Knodell score and other histologic parameters as predictors of response to interferon therapy in chronic hepatitis C Mod Pathol 1995 ; 8 : 232-8.
23. Piperno A, D'Alba R, Fargion S, Roffi L, Sampietro M, Parma S, et al. Liver iron concentration in chronic hepatitis : a study of 98 patients. Eur J Gastroenterol Hepatol 1995 ; 7 : 1203-8.
24. Castera L, Imbert-Bismut F, Fourré C, Dussaix E, Pawlotsky JM, Bedossa P, et al Do serum ferritin and hepatic iron concentration (HIC) predict response to interferon in patients with chronic hepatitis C (CHC) ? Hepatology 1997 , 24 494A.
25. Piperno A, D'Alba R, Fargion S, Roffi L, Sampietro M, Parma S, et al. Liver iron concentration in chronic hepatitis . a study of 98 patients. Eur J Gastroenterol Hepatol 1995 ; 7 . 1203-8.
26. Bacon BR, Fried MW, Di Bisceglie AM. A 39-year-old man with chronic hepatitis, elevated serum ferritin values, and a family history of hemochromatosis Semin Liver Dis 1993 ; 13 : 101-5
27. Yano M, Kakumu S, Hayashi H, Takikawa T, Nishimura N. Phlebotomy followed by α-interferon therapy in patients with chronic hepatitis C. Hepatology 1995 ; 22 . 119A
28. Han S-H, Tsai N, Morgan TR, Adkins R, Redeker AG, Fong T-L A pilot randomized, controlled trial of the effect of iron depletion on long term response to α-inferferon in patients with chronic hepatitis C virus. Hepatology 1996 , 24 : 1113
29. Bacon BR, Rebholz AE, Fried M, Di Bisceglie AM Beneficial effect fo iron reduction therapy in patients with chronic hepatitis C who railed to respond to interferon-α. Hepotology 1993 ; 18 90A.
30. Van Thiel DH, Friedlander L, Malloy P, Faguioli S, Wright HI, Gasbarinni A, et al. Retreatment of hepatitis C interferon non-responders with larger doses fo interferon with and without phlebotomy. Gastroenterology 1994 , 106 : A1002.
31. Zuckerman E, Tsai N, Han SH, Redeker AG, Fong TL Failure of iron depletion to improve response in chronic hepatitis C patients who were non-responders to prior interferon treatment. Hepatology 1996 , 24 604A.
32. Guyoder D, Boucher E, Even C, Cottereau J, Bianchi A, Gasser P, et al. Iron reduction therapy is inefficient in patients with chronic hepatitis C who failed to respond to interferon. Hepatology 1996 ; 24 405A.
33. Boucher E, Jouanolle H, Andre P, Ruffault A, Guyader D, Moirand R, et al. Interferon and ursodeoxycholic acid combined therapy in the treatment of chronic viral C hepatitis results from a controlled trial in 80 patients. Hepatology 1995 ; 21 : 322-7.
34. Simko V, Michael S, Prego V. Ursodeoxychotic therapy in chronic liver disease . a meta-analysis in primary biliary cirrhosis and in chronic hepatitis. Am J Gastroenterol 1994 ; 89 : 392-8.
35. Takano S, Ito Y, Yokosuka O, Ohto M, Uchiumi K, Hirota K, et al. A multicenter randomized controlled dose study of ursodeoxycholic acid for chronic hepatitis C. Hepatology 1994 , 20 558-64.
36. Puoti C, Magrini A, Filippi T, Annovazzi G, Pannullo A. Effects of ursodeoxycholic acid on serum liver enzymes in patients with hepatitis C virus related chronic liver disease. Eur J Gastroenterol Hepatol 1995 ; 7 151-4
37. Attili AF, Rusticali A, Varriale M, Carli L, Repice AM, Callea F, et al. The effect of ursodeoxycholic acid on serum enzymes and liver histology in patients with chronic active hepatitis : a 12-month double-blind, placebo-controlled trial. J Hepatol 1994 ; 20 315-20.
38. Podevin P, Calmus Y, Bonnefis MT, Veyrunes C, Chereau C, Poupon R. Effect of cholestasis and bile acids on interferon-induced 2′,5′-adenylate synthetase and NK cell activities. Gastroenterology 1995 ; 108 : 1192-8.
39. Serfaty L, Loria A, Giral P, Andreani P, Podevin P, Poupon R. Role of cholestasis and bile acids in resistance to recombinant alpha 2 interferon (INF) therapy in patients with chronic hepatitis C J Hepatol 1993 ; 18 (suppl 1) : S51
40. Van Thiel DH, Fiedlander U Malloy P, Wright HI, Gurakar A, Faguioli S, et al. γ-glutamyl transpeptidase as a response predictor when using α-interferon to treat hepatitis C. Hepato-Gastroenterol 1995 ; 42 888-92
41. Yoshikava M, Tsujii T, Matsumara K, Yamao J, Matsumara Y, Kubo R, et al. Immunomodulatory effects of ursodeoxycholic acid on immune responses. Hepatology 1992 ; 15 : 358-64.
42. Levy S, Capron JP, Erlinger S. Mécanisme d'action de l'acide ursodésoxycholique dans les maladies du foie cholestatiques. Gastroenterol Clin Biol 1996 , 20 . 549-59.
43. Mohler M, Seipp S, Tox U, Stremmel W, Theilmann L, Goeser T. Effect of ursodeoxycholic acid on HCV replication in subtyped chronic hepatitis C Dig Dis Sci 1996 ; 41 . 1276-7.
44. Lu CL, Chan CY, Hwang SJ, Lu RH, Lee SD. Efficacy of ursodeoxycholic acid in the treatment of patients with chronic hepatitis C. J Gastroenterol Hepatol 1995 ; 10 . 432-7.
45. Takiwaka H, Yamanaka M, Miyake K, Kako M, Ohki H, Narita T, et al Ursodeoxycholic acid therapy for chronic type C hepatitis - a multicenfer, dose finding trial. Curr Ther Res 1994 : 55 . 16-21
46. Angelico M, Gandin C, Pescarmona E, Rapicetta M, Del Vecchio C, Bini A, Recombinant interferon-alpha and ursodoxycholic acid versus interferon-alpha alone in the treatment of chronic hepatitis C . a randomized clinical trial with long term follow-up Am J Gastroenterol 1995 , 90 : 263-9.
47. Pigozzi MG, Sorbara R, Reggiani A, Valsecchi C, Lorini GP, Viviani G, et al Has tauro-ursodeoxycholic acid (T-UDCA) an interferon (IFN) sparing effect during treatment of chronic nepatitis C Gastroenterology 1996 , 110 . A1296.
48. Bottelli R, Bellati G, Alberti A, Vai C, Maggi G, Minola E, et al. Alpha interferon (α IFN) vs α IFN plus ursodeoxycholic acid (UDCA) in chronic hepatitis C (CH/C) . a controlled randomized trial. J Hepatol 1992 ; 16 (suppl 1) : S48
49. Bonnand A-M, Poupon R, Queneau P-M, Trépo C, Cohard M, Vetter D, et al. Interferon alfa and ursodeoxycholic acid combination versus interferon alone in the treatment of chronic hepatitis C : results of a randomized trial. Hepatology 1996 , 24 : 403A
50. Delich P, Hofmann OA, Luketic VA, Purdum PP, Sanval AJ, Mills AS, et al. Treatment of chronic hepatitis C with ursodeoxycholic acid in patients who failed interferon therapy. Gastroenterology 1995 ; 108 : A1057.
51. Lam NP, Pitrak D, Speralakis R, Lau AH, Wiley T, Layden TJ. Effect of obsesity on pharmakokinetics and biologic effect of interferon-α in hepatitis C. Dig Dis Sci 1997 , 42 : 178-85.
52. Davis GL Prediction of response to interferon treatment of chronic hepatitis C. J Hepatol 1994 ; 21 : 1-3.
53. Camps J, Crisostomo S, Garcia-Granero M, Riezu-Boj JI, Civeira MP, Prieto J. Prediction of the response of chronic hepatitis C to interferon alfa : a statistical analysis of pretreatment variables Gut 1993 ; 34 . 1714-7.
54. Chemello L, Cavaletto L, Noventa F, Bonetti P, Casarin C, Bernardinnello E, et al. Predictors of sustained response, relapse and no response in patients with chronic hepatitis C treated with interferon-alpha. J Viral Hepatitis 1995 , 2 91-6
55. Pawlotski JM, Roudot-Thoraval F, Bastie A, Darfhuy F, Rémiré J, Métreau JM, et al. Factors affecting treatment responses to interferon-α in chronic hepatitis C. J Infect Dis 1996 ; 174 . 1-7
56. Schvarcz R, Glaumann H, Weiland O, Norkrans G, Wejstal R, Fryden A Interferon alpha-2b treatment of chronic posttransfusion non-A, non-B/C hepatitis : long term outcome and effect of increased interferon doses in non responders Scand J Infect Dis 1991 ; 23 : 413-20.
57. Rosman AS, Waraich A, Galvin K, Casiano J, Paronetto F, Lieber CS Alcoholism is associated with hepatitis C but not hepatitis B in an urban population Am J Gastroenterol 1996 , 91 : 498-510
58. Mendenhall CL, Seeff L, Diehl AM, Ghosn SJ, French SW, Gartside PS, et al. Antibodies to hepatitis B virus and hepatitis C virus in alcoholic hepatitis and cirrhosis : their prevalence and clinical relevance. Hepatology 1991 ; 14 : 581-9
59. Caldwell SH, Jeffers LJ, Ditomaso A, Millar A, Clark RM, Rabassa A, et al. Antibody to hepatitis C is common among patients with alcoholic liver disease with and without risk factors. Am J Gastroenterol 1991 ; 86 1219-23.
60. Befrits R, Hedman M, Blomquist L, Allander T, Grillner L, Kinnman N, et al. Chronic hepatitis C in alcoholic patients : prevalence, genotypes, and correlation to liver disease. Scand J Gastroenterol 1995 , 30 . 1113-8.
61. Pares A, Barrera JM, Caballeria J, Ercilla G, Bruguera M, Caballeria L, et al Hepatitis C virus antibodies in chronic alcoholic patients : association with severity of liver injury Hepatology 1990 ; 12 . 1296-9
62. Cooksley WGE Chronic liver disease : do alcohol and hepatitis C virus interact ? J Gastroenterol Hepatol 1996 ; 11 . 187-92
63. Nishiguchi S, Kuroki T, Yabusako T, Seki S, Kobayashi K, Monna T, et al. Detection of hepatitis virus antibodies and hepatitis C virus RNA in patients with alcoholic liver disease Hepatology 1991 ; 14 : 985-9.
64. Noda K, Yoshihara K, Yamada Y, Kasahara A, Hayashi N, Fusamoto H, et al. Progression of type C chronic hepatitis to liver cirrhosis and hepatocellular carcinoma - its relationship to alcohol drinking and the age of transfusion Alcohol Clin Exp Res 1996 ; 20 95A-100A
65. Oshita M, Hayashi N, Kasahara A, Hagiwara H, Mita H, Naito M. Increased serum hepatitis C virus RNA levels among alcoholic patients with chronic hepatitis C. Hepatoiogy 1994 ; 20 . 1115-20.
66. Takase S, Takada N, Enomoto N, Yasuhara M, Takada A Different types of chronic hepatitis in alcoholic patients . does chronic hepatitis induced by alcohol exist ? Hepatology 1991 ; 13 . 871-81.
67. Pessione F, Martinot M, Duchatelle V, Njapoum C, Martins-Amado V, Degos F. L'alcool augmente la virémie chez les porteurs chroniques du virus de l'hépatite C. Gastroenterol Clin Biol 1996 ; 20 . A159
68. Okazaki T, Yoshihara H, Suzuki K, Yamada Y, Tsujimura T, Kawano K, et al. Efficacy of interferon therapy in patients with chronic hepatitis C. Comparison between non-drinkers and drinkers. Scand J Gastroenterol 1994 ; 29 : 1039-43.
69. Sata M, Fukuizumi K, Uchimura Y, Nakano H, Ishii K, Kumashiro R, et al Hepatitis C virus infection in patients with clinically diagnosed alcoholic liver diseases J Viral Hepatitis 1996 ; 3 143-8.
70. Ohnishi K, Matsuo S, Matsutani K, Itahashi M, Kakihara K, Suzuki K, et al. Interferon therapy for chronic hepatitis C in habitual drinkers : comparison with chronic hepatitis C in infrequent drinkers. Am J Gastroenterol 1996 ; 91 . 1374-9.
71. Mochida S, Ohnishi K, Matsuo S, Kakihara K, Fujiwara K, et al Effect of alcohol intake on the efficacy of interferon therapy in patients with chronic hepatitis C as evaluated by multivariate logistic regression analysis. Gastroenterology 1997 ; 24 . 276A